The Charta of Milan: Basic criteria for the appropriate and accurate use of antibiotics: Recommendations of the Italian society of chemotherapy

Journal of Chemotherapy

Volumn 21, Issue 5, 2009, Pages 475-481

  Scaglione, Francesco ^a   Bertazzoni Minelli, E ^b   De Sarro, A ^c   Esposito, S ^d   Legnani, D ^a   Mazzei, T ^e   Mini, E ^e   Passali, D ^f   Pea, F ^g   Stefani, S ^h   Viano, I ⁱ   Novelli, A ^e  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f UNIVERSITY OF SIENA   (Italy)

^g UNIVERSITY OF UDINE   (Italy)

^h UNIVERSITY OF CATANIA   (Italy)

ⁱ UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Antimicrobial agents; Antimicrobial resistance

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZITHROMYCIN; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; DAPTOMYCIN; GREPAFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; PENICILLIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN; TEMAFLOXACIN; TIGECYCLINE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; DRUG CHOICE; DRUG USE; HUMAN; INFECTION; ITALY; MEDICAL SOCIETY; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PRACTICE GUIDELINE; REVIEW; UNSPECIFIED SIDE EFFECT; COST BENEFIT ANALYSIS; HEALTH CARE ORGANIZATION; MULTIDRUG RESISTANCE; STANDARD;

ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE; HUMANS; INFECTION; ITALY; SOCIETIES, SCIENTIFIC;

EID: 75549085036     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2009.21.5.475     Document Type: Review

References (50)

1. Wenzel RP, Edmond MB. Managing antibiotic resistance. N Engl J Med. 2000;343:1961-1963.
2. Austin DJ, Kristinsson KG, Anderson RM. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci U S A. 1999;96:1152a-1156.
3. Low DE, Pichichero ME, Schaad UB. Optimizing antibacterial therapy for community-acquired respiratory tract infections in children in an era of bacterial resistance. Clin Pediatr. 2004;43:135-151.
4. Gonzales R, Malone DC, Maselli JH, Sande MA. Exces sive antibiotic use for acute respiratory infections in the United States. Clin Infect Dis. 2001;33:757-762.
5. McCaig LF, Besser RE, Hughes JM. Antimicrobial drug prescription in ambulatory care settings, United States, 1992-2000. Emerg Infect Dis. 2003;9:432-437.
6. Ball P, Baquero F, Cars O, et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother. 2002;49:31-40.
7. Gonzales R, Bartlett JG, Besser RE, et al. Principles of appropriate antibiotic use for treatment of acute respiratory tract infections in adults: background, specific aims, and methods. Ann Intern Med. 2001;134:479-486.
8. Del Mar CB, Glasziou PP, Spinks AB. Antibiotics for sore throat (Cochrane Review). Cochrane Collaboration. The Cochrane Library. Issue 1. Oxford: Update Software, 2003.
9. Smuckny J, Fahey T, Becker L, et al. Antibiotics for acute bronchitis (Cochrane Review). In: Cochrane Collaboration. The Cochrane Library. Issue 3. Oxford: Update Software, 2003.
10. Arroll B, Kenealy T. Antibiotics for the common cold and acute purulent rhinitis (Cochrane Review). In: Cochrane Collaboration. The Cochrane Library. Issue 3. Oxford: Update Software, 2003.
11. Fahey T, Stocks N, Thomas T. Quantitative systematic review of randomised controlled trials comparing antibiotic with placebo for acute cough in adults. BMJ 1998; 316: 906-910.
12. Glasziou PP, Del Mar CB, Sanders SL, Haymen M. Antibiotics for acute otitis media in children (Cochrane Review). In: Cochrane Collaboration. The Cochrane Library. Issue 3. Oxford: Update Software, 2003.
13. McCaig LF, Besser RE, Hughes JM. Trends in antimicrobial prescribing rates for children and adolescents. JAMA 2002; 287: 3096-3102.
14. Sapkota AR, Lefferts LY, Mckenzie S, Walker P. What do we feed to food-production animals? A review of animal feed ingredients and their potential impacts on human health. Environ Health Perspect. 2007;115(5):663-70.
15. Sarmah AK, Meyer MT, Boxall AB. A global perspective on the use, sales, exposure pathways, occurrence, fate and effects of veterinary antibiotics (vas) in the environment. Chemosphere. 2006; 65(5):725-59.
16. Viola C, Devincent SJ. Overview of issues pertaining to the manufacture, distribution, and use of antimicrobials in animals and other information relevant to animal antimicrobial use data collection in the United States. Prev Vet Med. 2006;73(2-3):111-31.
17. Bauchner H, Pelton SI, Klein JO. Parents, physicians, and antibiotic use. Pediatrics 1999; 103: 395-401.
18. Deas A, Crane LA, Baron AE, Gershman K, Maselli J, Gonzales R. Do physician attitudes about antibiotic resistance and appropriate antibiotic use correlate with actual antibiotic prescribing behavior?' J Gen Intern Med 2002; 17 (Suppl): 194.
19. Hamm RM, Hicks RJ, Bemben DA. Antibiotics and respiratory infections: are patients more satisfied when expectations are met? J Fam Pract 1996;43: 56-62.
20. Mangione-Smith R, McGlynn EA, Elliott MN, Krogstad P, Brook RH. The relationship between perceived parental expectations and pediatrician antimicrobial prescribing behavior. Pediatrics 1999;103: 711-8.
21. Maselli JH, Gonzales R. Measuring antibiotic prescribing practices among ambulatory physicians: accuracy of administrative claims data. J Clin Epidemiol 2001 ;54: 196-201.
22. Anon JB, Jacobs MR, Poole MD, et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg. 2004;130(suppl):1-45.
23. Woodhead M, Blasi F, Ewig S, Huchon G, Ieven M, Ortqviste A, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138-1180.
24. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al; Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Infectious Diseases Society of America; American Thoracic Society. Clin Infect Dis. 2007;44 Suppl 2:S27-72.
25. Preston SL. The importance of appropriate antimicrobial dosing: pharmacokinetic and pharmacodynamic considerations. Ann Pharmacother. 2004;38(9 Suppl):S14-8.
26. Scaglione F, Paraboni L. Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection. Expert Rev Anti Infect Ther. 2006;4(3):479-90. Review.
27. Craig WA. Pharmacokinetic/pharmacodynamic indices: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26: 1-12.
28. Craig WA. Does the dose matter? Clin Infect Dis 2001;33 (Suppl. 3), S233-S237.
29. Drusano GL. Prevention of resistance: A goal for dose selection of antimicrobial agents. Clin Infect Dis 2003:36 (Suppl. 1), S42-S50.
30. EUCAST. Setting breakpoints for new drugs and harmonising. www.srga.org/Eucastwt/bpsetting.htm - Visited November 2008.
31. Turnidge J, Christiansen K. Antibiotic use and resistance - proving the obvious. Lancet 2005;365:548-9.
32. Chung A, Perera R, Brueggemann AB, Elamin AE, Harnden A, Mayon-White R, et al. Effect of antibiotic prescribing on antibiotic resistance in individual children in primary care: prospective cohort study. BMJ. 2007;335(7617):429.
33. Goosens H, Ferech M, Stichele RV, Elseviers M. Outpatient antibiotic uses in Europe and association with resistance: a cross-national database study. Lancet 2005;365:579-87.
34. Arason VA, Gunnlaugsson A, Sigurdsson JA, Erlendsdottir H, Gudmundsson S, Kristinsson KG. Clonal spread of resistant pneumococci despite diminished antimicrobial use. Microb Drug Resist 2002;8:3-92.
35. Guillemot D, Carbon C, Balkau B, Geslin P, Lecoeur H, Vauzelle-Kervroëdan F, et al. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA. 1998;279(5):365-70.
36. Anderson VR, Perry CM. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs. 2008;68(4):535-65.
37. Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med. 2007 Sep;120(9):783-90.
38. Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother. 1998; 42: 521-527.
39. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287:2215-2220.
40. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004;351:1089-96.
41. Nicolau D. Clinical and economic implications of antimicrobial resistance for the management of community-acquired respiratory tract infections. J Antimicrob Chemother. 2002; 50 (suppl S1): 61-70.
42. Reyes S, Martinez R, Vallés JM, Cases E, Menendez R. Determinants of hospital costs in community-acquired pneumonia. Eur Respir J. 2008;31(5):1061-7.
43. Monte SV, Paolini NM, Slazak EM, Schentag JJ, Paladino JA. Costs of treating lower respiratory tract infections. Am J Manag Care. 2008;14(4):190-6.
44. Asche C, McAdam-Marx C, Seal B, Crookston B, Mullins CD. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance. J Antimicrob Chemother. 2008;61(5):1162-8.
45. Anderson VR, Perry CM. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs. 2008;68(4):535-65.
46. Hazir T, Fox LM, Nisar YB, Fox MP, Ashraf YP, MacLeod WB, et al. New outpatient short-course home oral therapy for severe pneumonia study group. Ambulatory short-course high-dose oral amoxicillin for treatment of severe pneumonia in children: a randomised equivalency trial. Lancet. 2008; 371 (9606): 49-56.
47. Poole MD, Portugal LG. Treatment of rhinosinusitis in the outpatient setting. Am J Med. 2005; 118 Suppl 7A:45S-50S.
48. Grossman RF, Rotschafer JC, Tan JS. Antimicrobial treatment of lower respiratory tract infections in the hospital setting. Am J Med. 2005;118 Suppl 7A:29S-38S.
49. Segreti J, House HR, Siegel RE. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. Am J Med. 2005;118 Suppl 7A:21S-28S.
50. Ball AP, Bartlett JG, Craig WA, Drusano GL, Felmingham D, Garau JA, et al. Future trends in antimicrobial chemotherapy: expert opinion on the 43rd ICAAC. J Chemother. 2004;16(5):419-36.